TICKERNERD
Menu
ADUSADUSHealthcare · Medical Care Facilities

ADUS Stock Forecast: Addus HomeCare Corp. Price Predictions for 2026-2027

Last close, 6 Aug 2026
$119
+1.99% on the day

The 14 Wall Street analysts covering Addus HomeCare Corp. hold a median 12-month price target of $135 — +13.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 6 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
95 / 100
Median analyst target
$135
Analysts covering
14
Total return, dividends reinvested
1W
+1.8%
1M
+12.3%
YTD
+10.6%
1Y
+3.3%
From 52W high
−3.2%
From 52W low
+34.2%
$88
$123
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADUS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Addus HomeCare Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Aug 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
87
Quality
82
Revisions
82
Issuance
81
Growth
81
Value
79
Accruals
64
Momentum
56
Size
35

Volatility (87): The share price has been relatively steady.

Momentum (56): The shares have been drifting down relative to others.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Addus HomeCare Corp. — and when they’d sell — is the membership.

Wall Street

ADUS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADUS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26ADUSHigh $155Median $135Low $96

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
12 Buy1 Hold1 Sell
Low $96Median $135High $155

The green dot is the last close — the median target sits +13.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026RBC CapitalMaintainsOutperform$130 → $134
9 July 2026BarclaysMaintainsUnderweight$92 → $96
18 May 2026CitizensReiteratesMarket Outperform—
15 May 2026BarclaysMaintainsUnderweight—
6 May 2026CitizensMaintainsMarket Outperform—
25 Mar 2026BarclaysMaintainsUnderweight—
25 Feb 2026Stephens & Co.MaintainsOverweight—
24 Feb 2026BarclaysMaintainsUnderweight—
13 Nov 2025BMO CapitalInitiatesMarket Perform—
7 Nov 2025RBC CapitalMaintainsOutperform—
5 Nov 2025TD CowenMaintainsBuy—
4 Nov 2025BarclaysMaintainsUnderweight—
3 Sept 2025Stephens & Co.ReiteratesOverweight—
2 Sept 2025UBSInitiatesBuy—
22 Aug 2025RBC CapitalMaintainsOutperform—
19 Aug 2025BarclaysMaintainsUnderweight—
6 Aug 2025TD CowenMaintainsBuy—
31 July 2025RBC CapitalMaintainsOutperform—
16 July 2025JMP SecuritiesReiteratesMarket Outperform—
20 June 2025JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ADUS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.6%
Analysts raising
12
Analysts cutting
1
Fundamentals

Addus HomeCare Corp. (ADUS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.5×

Cheaper than 37% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
1.9×

Cheaper than 48% of US stocks

EV / EBITDA
13.4×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
7.7%

Higher than 48% of US stocks

Earnings growth (YoY)
18.1%

Higher than 59% of US stocks

Gross margin
31.9%

Higher than 39% of US stocks

Operating margin
9.4%

Higher than 65% of US stocks

Net margin
6.9%

Higher than 64% of US stocks

Returns & dividend
Return on equity
9.4%

Higher than 62% of US stocks

Return on assets
6.3%

Higher than 83% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ADUS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
ADUSAddus HomeCare Corp.$2.2B
95
MDPediatrix Medical Group, Inc.$2.2B
100
AVAHAveanna Healthcare Holdings, Inc.$2.0B
90
GRDNGuardian Pharmacy Services, Inc.$2.5B
73
SGRYSurgery Partners, Inc.$1.9B
44
SNDASonida Senior Living, Inc.$1.9B
26
ACHCAcadia Healthcare Co., Inc.$2.8B
55
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADUS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ADUS news & analysis

ADUS vs. ELAN: Which Stock Is the Better Value Option?

Zacks Investment Research · 6 Aug 2026neutral

Zacks Investment Research published a piece comparing Addus HomeCare (ADUS) to Elanco Animal Health (ELAN), asking which of the two stocks currently offers value investors a better deal. Both are framed as stocks of interest to investors in medical outpatient and home healthcare.

Why it matters — The comparison highlights ADUS's valuation in relation to another company, which matters to ADUS watchers tracking how the stock is positioned for value-oriented investors.

Addus HomeCare Corporation (ADUS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Addus HomeCare Corporation held its Q2 2026 earnings call, during which management discussed the company's financial results and operational performance for the quarter.

Why it matters — The earnings call provides ADUS investors and analysts with direct commentary from management on the company's quarterly performance and near-term outlook.

Addus HomeCare Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026positive

Addus HomeCare reported second-quarter 2026 revenue growth of 8% and adjusted earnings-per-share growth of 16.1%, supported by expansion in personal care and hospice services, improved cash generation, and ongoing acquisition activity.

Why it matters — A watcher of Addus HomeCare would care because the company reported growth in revenue and adjusted earnings driven by service expansion, stronger cash flow, and acquisitions.

Addus HomeCare (ADUS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research · 3 Aug 2026neutral

Zacks reported on Addus HomeCare's (ADUS) earnings for the quarter ended June 2026, noting that the headline numbers show how the company performed and that it may be useful to compare key metrics against Wall Street estimates and the year-ago actuals.

Why it matters — For a ADUS watcher, the comparison of key metrics to Wall Street estimates and prior-year results helps gauge how the company's latest quarter measured up to expectations.

Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates

Zacks Investment Research · 3 Aug 2026positive

Addus HomeCare reported Q2 earnings of $1.73 per share, surpassing the Zacks Consensus Estimate of $1.69 per share. This compares with earnings of $1.49 per share in the same quarter a year ago, and the company also topped revenue estimates.

Why it matters — A quarter that beat both earnings and revenue expectations signals stronger-than-anticipated operating performance for Addus HomeCare.

FAQ

Frequently asked questions about ADUS stock

What is the ADUS stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Addus HomeCare Corp. have a median 12-month price target of $135, with estimates ranging from $96 to $155. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADUS stock a buy right now?

Of the 14 analysts covering Addus HomeCare Corp., 12 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Addus HomeCare Corp. 95 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADUS?

As at 6 Aug 2026, Addus HomeCare Corp. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (87 of 100).

Will ADUS stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +13.7% from the last close, and Ticker Nerd's factor model ranks Addus HomeCare Corp. 95 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADUS stock forecast for 2030?

No analyst covering Addus HomeCare Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $96 to $155 over the next 12 months.

How has ADUS stock performed over the past year?

Addus HomeCare Corp. returned +3.3% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Addus HomeCare Corp. do?

Addus HomeCare Corporation is a health care provider focused on delivering in-home personal care services throughout the United States. The company operates through three primary segments: Personal Care, which provides non-medical assistance with activities of daily living to elderly, chronically ill, and disabled individuals at risk of hospitalization or institutionalization; Hospice, which offers physical, emotional, and spiritual care for terminally ill patients and their families; and Home Health, which delivers medical services to individuals recovering from illness or surgery.

What is the latest news on ADUS?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "ADUS vs. ELAN: Which Stock Is the Better Value Option?". Zacks Investment Research published a piece comparing Addus HomeCare (ADUS) to Elanco Animal Health (ELAN), asking which of the two stocks currently offers value investors a better deal. Both are framed as stocks of interest to investors in medical outpatient and home healthcare.

Company

About Addus HomeCare Corp.

Addus HomeCare Corporation is a health care provider focused on delivering in-home personal care services throughout the United States. The company operates through three primary segments: Personal Care, which provides non-medical assistance with activities of daily living to elderly, chronically ill, and disabled individuals at risk of hospitalization or institutionalization; Hospice, which offers physical, emotional, and spiritual care for terminally ill patients and their families; and Home Health, which delivers medical services to individuals recovering from illness or surgery. Addus HomeCare serves a diverse patient population requiring supportive care in their homes rather than institutional settings. The company expands its service capabilities and geographic reach through both organic growth and strategic acquisitions, strengthening its position as a provider of essential home-based health care services. By enabling individuals to receive care in their homes, Addus HomeCare addresses a significant need within the health care system while supporting patient independence and quality of life.

CEO Mr. R. Dirk Allison CPA · 5,982 employees · United States · https://www.addus.com